VISION: An International Prospective Open Label Multicenter Randomized Phase 3 Study of 177Lu-PSMA-617 in the Treatment of Patients With Progressive PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC)
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
Conditions: prostate cancer
Age: Between 18 - 100 Years
In order to be eligible to take part in this trial, patients must meet the following criteria:
- Patients must have histological, pathological, and/or cytological confirmation of prostate cancer.
- Patients must have prior orchiectomy and/or ongoing androgen-deprivation therapy and a castrate level of serum testosterone (<50 ng/dL or <1.7 nmol/L).
For a full list of participation criteria, please visit clinicaltrials.gov.
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required